Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...

Sage Therapeutics has said it will cut its headcount by 40% in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the FDA, with two of the company's founders ...

Sage Therapeutics (NASDAQ:SAGE) announced a reorganization, including a workforce reduction of about 33%, to support the ongoing launch of ZURZUVAE for postpartum depression and to focus on ...

The setbacks include disappointing clinical trial results, a reduced US Food and Drug Administration (FDA) approval for its ...

Biogen will also make these resources available through a link on their Zurzuvae (zuranolone) patient website to help support women with PPD symptoms, in another example of the trend for pharma ...